# Dispatch Bio Raises $216M Series A for Solid-Tumor CAR-T Platform

> financing · REPORTED · 2025-10-01

Dispatch Bio raised $216 million in a Series A financing round to support clinical development of its Flare platform, a two-component CAR-T approach designed to broaden CAR-T applicability to solid tumors, with the first US Phase I study planned for 2026. Key investors include Sofinnova Investments, F-Prime Capital, Third Rock Ventures, and Alexandria Venture Investments.

About Dispatch Bio: Dispatch Bio is a clinical-stage biotech developing the Flare platform, which pairs a tumor-specific virus with a CAR-T cell therapy to expand CAR-T treatment to solid tumors where conventional CAR-T has largely failed.

- Company: Dispatch Bio
- Sector: oncology
- Primary source: https://xtalks.com/biotech-funding-2025-tracker-follow-the-latest-raises-rounds-and-rd-momentum-4542/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.